Table 3.
Characteristics of patients achieving ≥5-year survival without disease recurrence after systemic therapy plus RFA for liver-only CLM
|
Patient |
Systemic therapy |
Clinical features |
||||
|---|---|---|---|---|---|---|
| Response 1 | No. of lines | Regimen(s) administered | Number of CLM | Size 2 of CLM | CEA level (ng/ml) | |
| 1 |
Partial remission |
1 |
FOLFIRI |
1 |
2.5 cm |
12 |
| 2 |
Partial remission |
2 |
FOLFOX, FOLFIRI |
1 |
2.1 cm |
23 |
| 3 |
Partial remission |
1 |
FOLFOX |
2 |
2.2 cm |
13 |
| 4 |
Partial remission |
2 |
FOLFIRI + Bevacizumab, FOLFOX + Cetuximab |
3 |
3.0 cm |
114 |
| 5 |
Partial remission |
1 |
FOLFIRI + Bevacizumab |
2 |
3.1 cm |
57 |
| 6 | Partial remission | 1 | FOLFOX | 1 | 2.7 cm | 4 |
Abbreviations: CEA, carcinoembryonic antigen; CLM, colorectal liver metastases; FOLFIRI, 5-fluorouracil, leucovorin, irinotecan; FOLFOX, 5-fluorouracil, leucovorin, oxaliplatin; RFA, radiofrequency ablation.
1RECIST-defined response to the immediate preceding regimen before RFA treatment. 2after decrease of ≥30% in size following the immediate preceding regimen before RFA treatment.